Barbiturates bind within the chloride channel pore of the gamma-aminobutyric acid type A receptor and increase the duration of chloride channel opening, in contrast to benzodiazepines which increase the frequency of opening. At therapeutic concentrations, gamma-aminobutyric acid must be present for barbiturates to work. However, at supratherapeutic concentrations, barbiturates can directly activate the chloride channel without gamma-aminobutyric acid — a property benzodiazepines lack entirely. This direct channel activation underlies the profound, dose-dependent central nervous system depression of barbiturate toxicity: respiratory depression, cardiovascular collapse, and death. There is no ceiling on this effect.

Barbiturates also inhibit excitatory AMPA-type glutamate receptors, giving them a dual mechanism of enhancing inhibition and suppressing excitation. This dual action is particularly relevant in refractory status epilepticus, where gamma-aminobutyric acid type A receptor downregulation reduces benzodiazepine efficacy, but glutamate receptor antagonism provides an additional mechanism to terminate seizures.

Phenobarbital is the longest-acting barbiturate (half-life 80 to 120 hours) and the one with the broadest current clinical use. Its primary indications include neonatal seizures, where it remains first-line at most institutions; refractory status epilepticus, as a recognized third-line agent when benzodiazepines and second-line agents have failed; and alcohol and benzodiazepine withdrawal management, where fixed-dose intravenous phenobarbital loading is experiencing a clinical resurgence backed by prospective data showing reduced benzodiazepine requirements and lower rates of delirium tremens compared to benzodiazepine-only protocols.

The pharmacological rationale for phenobarbital in severe alcohol withdrawal is compelling: at high concentrations it directly activates gamma-aminobutyric acid type A channels, bypassing the receptor downregulation that limits benzodiazepine efficacy in severe withdrawal; it inhibits AMPA receptors, attenuating excitatory withdrawal pathophysiology; and its long half-life provides smooth, self-tapering coverage. Full discussion of withdrawal protocols is in Module 4.

Thiopental is an ultra-short-acting barbiturate with extremely high lipophilicity, producing unconsciousness within one arm-to-brain circulation time after intravenous administration. Its rapid offset is due to redistribution from the brain to peripheral tissues rather than metabolism. It has been largely supplanted by propofol for routine anesthesia induction and is no longer commercially available in the United States.

Pentobarbital retains two specific current applications: procedural sedation for pediatric diagnostic imaging, and pentobarbital coma for refractory intracranial hypertension in neurocritical care, where deep barbiturate sedation reduces cerebral metabolic demand and intracranial pressure. Pentobarbital coma requires continuous electroencephalogram monitoring for burst suppression titration, continuous hemodynamic monitoring, and mechanical ventilation.

Propofol is the most widely used intravenous sedative-hypnotic in contemporary clinical practice. Its mechanism is primarily positive allosteric modulation of the gamma-aminobutyric acid type A receptor, with possible additional effects at N-methyl-D-aspartate receptors and sodium channels. Its defining clinical properties are its extremely rapid onset (15 to 45 seconds intravenously), short context-sensitive half-life (approximately 2 to 24 minutes after short infusions, extending with prolonged use), and smooth, titratable control of sedation depth.

Propofol produces dose-dependent respiratory depression and apnea; airway management capability is mandatory whenever it is used. Hypotension is common, driven by decreased systemic vascular resistance and mild myocardial depression. Propofol is formulated in a lipid emulsion that supports microbial growth if strict aseptic technique is not maintained — contaminated infusions have caused serious infections and fatalities. Propofol provides no analgesia and must be combined with analgesics when pain management is required alongside sedation.

Dexmedetomidine is a highly selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis through a mechanism entirely distinct from gamma-aminobutyric acid modulation. It acts primarily on alpha-2 receptors in the locus coeruleus — the principal noradrenergic nucleus governing arousal — inhibiting norepinephrine release and reducing ascending arousal signaling to the cortex. The result is a sedative state that closely resembles natural sleep.

The defining clinical advantage of dexmedetomidine is that patients remain readily arousable and cooperative during sedation — neurological assessment and patient interaction are possible at sedation depths where propofol or benzodiazepines would render the patient unresponsive. It also produces significantly less respiratory depression than other sedatives, making it valuable when avoiding respiratory compromise is a priority. Primary adverse effects are bradycardia and hypotension from sympatholytic activity; transient hypertension may paradoxically occur with rapid loading due to peripheral alpha-2B receptor stimulation.

Ketamine is a dissociative anesthetic whose primary mechanism is non-competitive antagonism of N-methyl-D-aspartate glutamate receptors, blocking calcium influx through the open channel pore. Unlike all other intravenous sedatives, ketamine increases sympathetic tone by inhibiting neuronal catecholamine reuptake, producing increases in heart rate, blood pressure, and cardiac output. This makes it the induction agent of choice in hemodynamically compromised patients — hemorrhagic shock, severe bronchospasm, cardiac tamponade — where other agents would cause dangerous hypotension.

Ketamine produces a dissociative state with analgesia, amnesia, and sedation while maintaining airway protective reflexes (though this is not absolute, and airway management capability must always be available). Bronchodilation via its sympathomimetic effects makes it the agent of choice for procedural sedation in patients with severe reactive airway disease. At subanesthetic doses it provides potent analgesia useful in emergency and critical care settings. An important emerging application is treatment-resistant depression: intravenous ketamine infusions produce rapid antidepressant effects within hours — in contrast to the two to six week latency of conventional antidepressants — a clinically transformative property for acutely suicidal patients. Esketamine (the S-enantiomer) is available as an intranasal formulation for treatment-resistant depression, administered in a certified healthcare setting.

The most clinically problematic adverse effects are emergence reactions: vivid, often disturbing hallucinations and delirium during recovery, occurring in approximately 10 to 15 percent of patients at anesthetic doses. Pre-treatment or co-administration with midazolam substantially reduces their incidence. Ketamine also increases oral secretions; glycopyrrolate can be given prophylactically. Elevated intraocular pressure and relative contraindication in active psychosis or schizophrenia are additional considerations.

Etomidate is an imidazole-derived intravenous hypnotic that positively modulates the gamma-aminobutyric acid type A receptor. Its defining characteristic is exceptional hemodynamic stability — it produces minimal changes in heart rate, blood pressure, and cardiac output compared to all other induction agents, making it the preferred choice for hemodynamically unstable patients when ketamine is contraindicated.

Etomidate's most clinically significant adverse effect is adrenocortical suppression. It inhibits 11-beta-hydroxylase, the enzyme required for cortisol synthesis in the adrenal cortex, producing transient adrenal insufficiency lasting 12 to 24 hours after a single induction dose and substantially longer with continuous infusion. Continuous etomidate infusion for intensive care unit sedation has been abandoned because of this effect. The clinical significance of single-dose adrenal suppression in septic shock remains debated, and its use in rapid sequence intubation of septic patients continues to be evaluated. Myoclonus on induction (in 40 to 80 percent of patients) is reduced by benzodiazepine pretreatment. Etomidate is also the most emetogenic of the intravenous induction agents.